Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 292

1.

Effectiveness of fluticasone furoate plus vilanterol on asthma control in clinical practice: an open-label, parallel group, randomised controlled trial.

Woodcock A, Vestbo J, Bakerly ND, New J, Gibson JM, McCorkindale S, Jones R, Collier S, Lay-Flurrie J, Frith L, Jacques L, Fletcher JL, Harvey C, Svedsater H, Leather D; Salford Lung Study Investigators.

Lancet. 2017 Sep 10. pii: S0140-6736(17)32397-8. doi: 10.1016/S0140-6736(17)32397-8. [Epub ahead of print]

PMID:
28903864
2.

Hepatocellular carcinoma risk following direct-acting antiviral HCV therapy: A systematic review, meta-analyses, and meta-regression.

Waziry R, Hajarizadeh B, Grebely J, Amin J, Law M, Danta M, George J, Dore GJ.

J Hepatol. 2017 Aug 9. pii: S0168-8278(17)32199-2. doi: 10.1016/j.jhep.2017.07.025. [Epub ahead of print]

PMID:
28802876
3.
4.

Week 96 results of the randomized, multicentre Maraviroc Switch (MARCH) study.

Pett SL, Amin J, Horban A, Andrade-Villanueva J, Losso M, Porteiro N, Madero JS, Belloso W, Tu E, Silk D, Kelleher A, Harrigan R, Clark A, Sugiura W, Wolff M, Gill J, Gatell J, Clarke A, Ruxrungtham K, Prazuck T, Kaiser R, Woolley I, Alberto Arnaiz J, Cooper D, Rockstroh JK, Mallon P, Emery S; MARCH study group.

HIV Med. 2017 Jul 13. doi: 10.1111/hiv.12532. [Epub ahead of print]

PMID:
28703491
5.

HIV-1 Env- and Vpu-Specific Antibody-Dependent Cellular Cytotoxicity Responses Associated with Elite Control of HIV.

Madhavi V, Wines BD, Amin J, Emery S; ENCORE1 Study Group, Lopez E, Kelleher A; Sydney LTNP Study Group, Center RJ, Hogarth PM, Chung AW, Kent SJ, Stratov I.

J Virol. 2017 Aug 24;91(18). pii: e00700-17. doi: 10.1128/JVI.00700-17. Print 2017 Sep 15.

PMID:
28701393
6.

Changes in risk behaviours during and following treatment for hepatitis C virus infection among people who inject drugs: The ACTIVATE study.

Midgard H, Hajarizadeh B, Cunningham EB, Conway B, Backmund M, Bruggmann P, Bruneau J, Bourgeois S, Dunlop A, Foster GR, Hellard M, Robaeys G, Thurnheer MC, Weltman M, Amin J, Marks PS, Quiene S, Dore GJ, Dalgard O, Grebely J; ACTIVATE Study Group.

Int J Drug Policy. 2017 Sep;47:230-238. doi: 10.1016/j.drugpo.2017.05.040. Epub 2017 Jun 19.

PMID:
28633998
7.

Efficacy of response-guided directly observed pegylated interferon and self-administered ribavirin for people who inject drugs with hepatitis C virus genotype 2/3 infection: The ACTIVATE study.

Grebely J, Dalgard O, Cunningham EB, Hajarizadeh B, Foster GR, Bruggmann P, Conway B, Backmund M, Robaeys G, Swan T, Amin J, Marks PS, Quiene S, Applegate TL, Weltman M, Shaw D, Dunlop A, Hellard M, Bruneau J, Midgard H, Bourgeois S, Staehelin C, Dore GJ; ACTIVATE Study Group.

Int J Drug Policy. 2017 Sep;47:177-186. doi: 10.1016/j.drugpo.2017.05.020. Epub 2017 Jun 16.

PMID:
28624134
8.

Adherence to response-guided pegylated interferon and ribavirin for people who inject drugs with hepatitis C virus genotype 2/3 infection: the ACTIVATE study.

Cunningham EB, Hajarizadeh B, Dalgard O, Amin J, Hellard M, Foster GR, Bruggmann P, Conway B, Backmund M, Robaeys G, Swan T, Marks PS, Quiene S, Applegate TL, Weltman M, Shaw D, Dunlop A, Bruneau J, Midgard H, Bourgeois S, Thurnheer MC, Dore GJ, Grebely J; ACTIVATE Study Group.

BMC Infect Dis. 2017 Jun 13;17(1):420. doi: 10.1186/s12879-017-2517-3.

9.

Anti-HIV-1 ADCC Antibodies following Latency Reversal and Treatment Interruption.

Lee WS, Kristensen AB, Rasmussen TA, Tolstrup M, Østergaard L, Søgaard OS, Wines BD, Hogarth PM, Reynaldi A, Davenport MP, Emery S, Amin J, Cooper DA, Kan VL, Fox J, Gruell H, Parsons MS, Kent SJ.

J Virol. 2017 Jul 12;91(15). pii: e00603-17. doi: 10.1128/JVI.00603-17. Print 2017 Aug 1.

PMID:
28539449
10.

Evacetrapib and Cardiovascular Outcomes in High-Risk Vascular Disease.

Lincoff AM, Nicholls SJ, Riesmeyer JS, Barter PJ, Brewer HB, Fox KAA, Gibson CM, Granger C, Menon V, Montalescot G, Rader D, Tall AR, McErlean E, Wolski K, Ruotolo G, Vangerow B, Weerakkody G, Goodman SG, Conde D, McGuire DK, Nicolau JC, Leiva-Pons JL, Pesant Y, Li W, Kandath D, Kouz S, Tahirkheli N, Mason D, Nissen SE; ACCELERATE Investigators.

N Engl J Med. 2017 May 18;376(20):1933-1942. doi: 10.1056/NEJMoa1609581.

PMID:
28514624
11.

Divergent roles of a peripheral transmembrane segment in AMPA and NMDA receptors.

Amin JB, Salussolia CL, Chan K, Regan MC, Dai J, Zhou HX, Furukawa H, Bowen ME, Wollmuth LP.

J Gen Physiol. 2017 Jun 5;149(6):661-680. doi: 10.1085/jgp.201711762. Epub 2017 May 15.

PMID:
28507080
12.

Evaluation of the Xpert HCV Viral Load point-of-care assay from venepuncture-collected and finger-stick capillary whole-blood samples: a cohort study.

Grebely J, Lamoury FMJ, Hajarizadeh B, Mowat Y, Marshall AD, Bajis S, Marks P, Amin J, Smith J, Edwards M, Gorton C, Ezard N, Persing D, Kleman M, Cunningham P, Catlett B, Dore GJ, Applegate TL; LiveRLife Study Group.

Lancet Gastroenterol Hepatol. 2017 Jul;2(7):514-520. doi: 10.1016/S2468-1253(17)30075-4. Epub 2017 Apr 22.

PMID:
28442271
13.

Tracheostomy for Severe Pediatric Obstructive Sleep Apnea: Indications and Outcomes.

Rizzi CJ, Amin JD, Isaiah A, Valdez TA, Jeyakumar A, Smart SE, Pereira KD.

Otolaryngol Head Neck Surg. 2017 Aug;157(2):309-313. doi: 10.1177/0194599817702369. Epub 2017 Apr 18.

PMID:
28417683
14.

Effect of Combination Antiretroviral Therapy on HIV-1-specific Antibody-Dependent Cellular Cytotoxicity Responses in Subtype B- and Subtype C-Infected Cohorts.

Madhavi V, Kulkarni A, Shete A, Lee WS, Mclean MR, Kristensen AB, Ghate M, Wines BD, Hogarth PM, Parsons MS, Kelleher A, Cooper DA, Amin J, Emery S, Thakar M, Kent SJ; ENCORE1 Study Group.

J Acquir Immune Defic Syndr. 2017 Jul 1;75(3):345-353. doi: 10.1097/QAI.0000000000001380.

PMID:
28346319
15.

Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease.

Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, Kuder JF, Wang H, Liu T, Wasserman SM, Sever PS, Pedersen TR; FOURIER Steering Committee and Investigators.

N Engl J Med. 2017 May 4;376(18):1713-1722. doi: 10.1056/NEJMoa1615664. Epub 2017 Mar 17.

PMID:
28304224
16.

Ongoing incident hepatitis C virus infection among people with a history of injecting drug use in an Australian prison setting, 2005-2014: The HITS-p study.

Cunningham EB, Hajarizadeh B, Bretana NA, Amin J, Betz-Stablein B, Dore GJ, Luciani F, Teutsch S, Dolan K, Lloyd AR, Grebely J; HITS-p investigators.

J Viral Hepat. 2017 Sep;24(9):733-741. doi: 10.1111/jvh.12701. Epub 2017 Apr 10.

PMID:
28256027
17.

Comparing the effects of peritonsillar infiltration of tramadol before and after the surgery on post-tonsillectomy pain.

Maryam H, Amin J, Sedighe V, Vida A.

Eur Arch Otorhinolaryngol. 2017 Jun;274(6):2521-2527. doi: 10.1007/s00405-017-4477-z. Epub 2017 Mar 1.

PMID:
28251321
18.

Treatment efficacy of azithromycin 1 g single dose versus doxycycline 100 mg twice daily for 7 days for the treatment of rectal chlamydia among men who have sex with men - a double-blind randomised controlled trial protocol.

Lau A, Kong F, Fairley CK, Donovan B, Chen M, Bradshaw C, Boyd M, Amin J, Timms P, Tabrizi S, Regan DG, Lewis DA, McNulty A, Hocking JS.

BMC Infect Dis. 2017 Jan 6;17(1):35. doi: 10.1186/s12879-016-2125-7.

19.

What do we know about the inflammasome in humans?

Amin J, Boche D, Rakic S.

Brain Pathol. 2017 Mar;27(2):192-204. doi: 10.1111/bpa.12479.

PMID:
27997042
20.

Ticagrelor versus Clopidogrel in Symptomatic Peripheral Artery Disease.

Hiatt WR, Fowkes FG, Heizer G, Berger JS, Baumgartner I, Held P, Katona BG, Mahaffey KW, Norgren L, Jones WS, Blomster J, Millegård M, Reist C, Patel MR; EUCLID Trial Steering Committee and Investigators.

N Engl J Med. 2017 Jan 5;376(1):32-40. doi: 10.1056/NEJMoa1611688. Epub 2016 Nov 13.

Supplemental Content

Loading ...
Support Center